10X GENOMICS, INC. (TXG): Price and Financial Metrics


Today's Latest Price: $149.04 USD

3.82 (2.63%)

Updated Dec 4 4:00pm

Add TXG to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 70 in Medical - Services

See all "A" rated Strong Buy stocks

TXG Stock Summary

  • With a one year PEG ratio of 0.47, 10x Genomics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.11% of US stocks.
  • TXG's went public 1.23 years ago, making it older than just 1.32% of listed US stocks we're tracking.
  • TXG's price/sales ratio is 59.49; that's higher than the P/S ratio of 95.91% of US stocks.
  • Stocks that are quantitatively similar to TXG, based on their financial statements, market capitalization, and price volatility, are ESTC, WIX, GWPH, PEGA, and SMAR.
  • TXG's SEC filings can be seen here. And to visit 10x Genomics Inc's official web site, go to www.10xgenomics.com.

TXG Stock Price Chart Interactive Chart >

Price chart for TXG

TXG Price/Volume Stats

Current price $149.04 52-week high $166.31
Prev. close $145.22 52-week low $48.78
Day low $144.26 Volume 661,500
Day high $149.49 Avg. volume 702,533
50-day MA $142.27 Dividend yield N/A
200-day MA $100.03 Market Cap 14.96B

10X GENOMICS, INC. (TXG) Company Bio

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

TXG Latest News Stream

Event/Time News Detail
Loading, please wait...

TXG Latest Social Stream

Loading social stream, please wait...

View Full TXG Social Stream

Latest TXG News From Around the Web

Below are the latest news stories about 10x Genomics Inc that investors may wish to consider to help them evaluate TXG as an investment opportunity.

The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...

Benzinga | September 29, 2020

Single-Cell Genome Sequencing (SCGS) Market Rising Demand and its Analysis by 10x Genomics, Fluidigm, Novogene, QIAGEN

A report by The Insight Partner's on the global Single-Cell Genome Sequencing (SCGS) market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive

OpenPR | September 28, 2020

The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ...

Benzinga | September 15, 2020

10x Genomics prices upsized stock offering at $110

10x Genomics (TXG) has priced upsized public offering of its 4M (from 3.5M) Class A common stock at $110.00/share, at a discounted price from Sept. 10 close of $113.51.Underwriters' over-allotment is an additional 600K shares.Closing date is September 15.10x Genomics has rebounded from March lows of around $51 to around...

Seeking Alpha | September 11, 2020

10x Genomics Announces Pricing of Upsized Public Offering

PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ:TXG) (the "Company") today announced the pricing of an upsized …

Benzinga | September 10, 2020

Read More 'TXG' Stories Here

TXG Price Returns

1-mo 0.30%
3-mo 40.17%
6-mo 84.00%
1-year 135.04%
3-year N/A
5-year N/A
YTD 95.46%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6853 seconds.